Selective increase of two ABC drug efflux transporters at the blood-spinal cord barrier suggests induced pharmacoresistance in ALS

Michael R. Jablonski, Dena A. Jacob, Christopher Campos, David S. Miller, Nicholas J Maragakis, Piera Pasinelli, Davide Trotti

Research output: Contribution to journalArticle

Abstract

ATP-binding cassette (ABC) drug efflux transporters in the CNS are predominantly localized to the luminal surface of endothelial cells in capillaries to impede CNS accumulation of xenobiotics. Inflammatory mediators and cellular stressors regulate their activity. Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of upper and lower motor neurons characterized by extensive neuroinflammation. Here we tested the hypothesis that disease-driven changes in ABC transporter expression and function occur in ALS. Given the multitude of ABC transporters with their widespread substrate recognition, we began by examining expression levels of several ABC transporters. We found a selective increase in only two transporters: P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) both at mRNA and protein levels, in the SOD1-G93A mouse model of ALS, specifically in disease-affected CNS regions. Detailed analysis revealed a similar disease-driven increase in P-gp and BCRP levels in spinal cord microvessels, indicating that their altered expression occurs at the blood spinal cord barrier. Transport activity of P-gp and BCRP increased with disease progression in spinal cord and cerebral cortex capillaries. Finally, P-gp and BCRP protein expression also increased in spinal cords of ALS patients. Preclinical drug trials in the mouse model of ALS have failed to decisively slow or arrest disease progression; pharmacoresistance imparted by ABC transporters is one possible explanation for these failures. Our observations have large implications for ALS therapeutics in humans and suggest that the obstacle provided by these transporters to drug treatments must be overcome to develop effective ALS pharmacotherapies.

Original languageEnglish (US)
Pages (from-to)194-200
Number of pages7
JournalNeurobiology of Disease
Volume47
Issue number2
DOIs
StatePublished - Aug 2012

Fingerprint

Amyotrophic Lateral Sclerosis
Spinal Cord
Adenosine Triphosphate
ATP-Binding Cassette Transporters
P-Glycoprotein
Pharmaceutical Preparations
Breast Neoplasms
Proteins
Disease Progression
Central Nervous System Diseases
Motor Neurons
Xenobiotics
Microvessels
Neurodegenerative Diseases
Cerebral Cortex
Endothelial Cells
Drug Therapy
Messenger RNA
Therapeutics

Keywords

  • ABC transporters
  • Amyotrophic Lateral Sclerosis
  • Blood-brain barrier
  • Blood-spinal cord barrier
  • Breast cancer resistance protein
  • P-glycoprotein
  • Pharmacoresistance

ASJC Scopus subject areas

  • Neurology

Cite this

Selective increase of two ABC drug efflux transporters at the blood-spinal cord barrier suggests induced pharmacoresistance in ALS. / Jablonski, Michael R.; Jacob, Dena A.; Campos, Christopher; Miller, David S.; Maragakis, Nicholas J; Pasinelli, Piera; Trotti, Davide.

In: Neurobiology of Disease, Vol. 47, No. 2, 08.2012, p. 194-200.

Research output: Contribution to journalArticle

Jablonski, Michael R. ; Jacob, Dena A. ; Campos, Christopher ; Miller, David S. ; Maragakis, Nicholas J ; Pasinelli, Piera ; Trotti, Davide. / Selective increase of two ABC drug efflux transporters at the blood-spinal cord barrier suggests induced pharmacoresistance in ALS. In: Neurobiology of Disease. 2012 ; Vol. 47, No. 2. pp. 194-200.
@article{37e83cddd49449278fb83682ec30ea10,
title = "Selective increase of two ABC drug efflux transporters at the blood-spinal cord barrier suggests induced pharmacoresistance in ALS",
abstract = "ATP-binding cassette (ABC) drug efflux transporters in the CNS are predominantly localized to the luminal surface of endothelial cells in capillaries to impede CNS accumulation of xenobiotics. Inflammatory mediators and cellular stressors regulate their activity. Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of upper and lower motor neurons characterized by extensive neuroinflammation. Here we tested the hypothesis that disease-driven changes in ABC transporter expression and function occur in ALS. Given the multitude of ABC transporters with their widespread substrate recognition, we began by examining expression levels of several ABC transporters. We found a selective increase in only two transporters: P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) both at mRNA and protein levels, in the SOD1-G93A mouse model of ALS, specifically in disease-affected CNS regions. Detailed analysis revealed a similar disease-driven increase in P-gp and BCRP levels in spinal cord microvessels, indicating that their altered expression occurs at the blood spinal cord barrier. Transport activity of P-gp and BCRP increased with disease progression in spinal cord and cerebral cortex capillaries. Finally, P-gp and BCRP protein expression also increased in spinal cords of ALS patients. Preclinical drug trials in the mouse model of ALS have failed to decisively slow or arrest disease progression; pharmacoresistance imparted by ABC transporters is one possible explanation for these failures. Our observations have large implications for ALS therapeutics in humans and suggest that the obstacle provided by these transporters to drug treatments must be overcome to develop effective ALS pharmacotherapies.",
keywords = "ABC transporters, Amyotrophic Lateral Sclerosis, Blood-brain barrier, Blood-spinal cord barrier, Breast cancer resistance protein, P-glycoprotein, Pharmacoresistance",
author = "Jablonski, {Michael R.} and Jacob, {Dena A.} and Christopher Campos and Miller, {David S.} and Maragakis, {Nicholas J} and Piera Pasinelli and Davide Trotti",
year = "2012",
month = "8",
doi = "10.1016/j.nbd.2012.03.040",
language = "English (US)",
volume = "47",
pages = "194--200",
journal = "Neurobiology of Disease",
issn = "0969-9961",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Selective increase of two ABC drug efflux transporters at the blood-spinal cord barrier suggests induced pharmacoresistance in ALS

AU - Jablonski, Michael R.

AU - Jacob, Dena A.

AU - Campos, Christopher

AU - Miller, David S.

AU - Maragakis, Nicholas J

AU - Pasinelli, Piera

AU - Trotti, Davide

PY - 2012/8

Y1 - 2012/8

N2 - ATP-binding cassette (ABC) drug efflux transporters in the CNS are predominantly localized to the luminal surface of endothelial cells in capillaries to impede CNS accumulation of xenobiotics. Inflammatory mediators and cellular stressors regulate their activity. Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of upper and lower motor neurons characterized by extensive neuroinflammation. Here we tested the hypothesis that disease-driven changes in ABC transporter expression and function occur in ALS. Given the multitude of ABC transporters with their widespread substrate recognition, we began by examining expression levels of several ABC transporters. We found a selective increase in only two transporters: P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) both at mRNA and protein levels, in the SOD1-G93A mouse model of ALS, specifically in disease-affected CNS regions. Detailed analysis revealed a similar disease-driven increase in P-gp and BCRP levels in spinal cord microvessels, indicating that their altered expression occurs at the blood spinal cord barrier. Transport activity of P-gp and BCRP increased with disease progression in spinal cord and cerebral cortex capillaries. Finally, P-gp and BCRP protein expression also increased in spinal cords of ALS patients. Preclinical drug trials in the mouse model of ALS have failed to decisively slow or arrest disease progression; pharmacoresistance imparted by ABC transporters is one possible explanation for these failures. Our observations have large implications for ALS therapeutics in humans and suggest that the obstacle provided by these transporters to drug treatments must be overcome to develop effective ALS pharmacotherapies.

AB - ATP-binding cassette (ABC) drug efflux transporters in the CNS are predominantly localized to the luminal surface of endothelial cells in capillaries to impede CNS accumulation of xenobiotics. Inflammatory mediators and cellular stressors regulate their activity. Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of upper and lower motor neurons characterized by extensive neuroinflammation. Here we tested the hypothesis that disease-driven changes in ABC transporter expression and function occur in ALS. Given the multitude of ABC transporters with their widespread substrate recognition, we began by examining expression levels of several ABC transporters. We found a selective increase in only two transporters: P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) both at mRNA and protein levels, in the SOD1-G93A mouse model of ALS, specifically in disease-affected CNS regions. Detailed analysis revealed a similar disease-driven increase in P-gp and BCRP levels in spinal cord microvessels, indicating that their altered expression occurs at the blood spinal cord barrier. Transport activity of P-gp and BCRP increased with disease progression in spinal cord and cerebral cortex capillaries. Finally, P-gp and BCRP protein expression also increased in spinal cords of ALS patients. Preclinical drug trials in the mouse model of ALS have failed to decisively slow or arrest disease progression; pharmacoresistance imparted by ABC transporters is one possible explanation for these failures. Our observations have large implications for ALS therapeutics in humans and suggest that the obstacle provided by these transporters to drug treatments must be overcome to develop effective ALS pharmacotherapies.

KW - ABC transporters

KW - Amyotrophic Lateral Sclerosis

KW - Blood-brain barrier

KW - Blood-spinal cord barrier

KW - Breast cancer resistance protein

KW - P-glycoprotein

KW - Pharmacoresistance

UR - http://www.scopus.com/inward/record.url?scp=84861683789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861683789&partnerID=8YFLogxK

U2 - 10.1016/j.nbd.2012.03.040

DO - 10.1016/j.nbd.2012.03.040

M3 - Article

C2 - 22521463

AN - SCOPUS:84861683789

VL - 47

SP - 194

EP - 200

JO - Neurobiology of Disease

JF - Neurobiology of Disease

SN - 0969-9961

IS - 2

ER -